Ranbaxy Reports Corrections At Dewas Plant To U.S. FDA; Hopes Import Restrictions Will Be Lifted Soon
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - Part of Ranbaxy's troubles with its manufacturing units in India may be coming to an end in the next few months; the company has filed an exhaustive report with the U.S. FDA on corrections made at its manufacturing facilities at Dewas
You may also be interested in...
In the wake of the Ranbaxy settlement, Wockhardt is the latest Indian company to be issued an import alert for alleged GMP violations.